Bulletin
Investor Alert

New York Markets Close in:

Market Pulse Archives

Aug. 17, 2022, 2:59 p.m. EDT

Bluebird announces FDA approval of gene therapy for rare blood disease

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    bluebird bio Inc. (BLUE)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Buebird Bio Inc. /zigman2/quotes/207450173/composite BLUE -5.45% jumped 12.1% in trading on Wednesday after the Food and Drug Administration approved the company's gene therapy as a treatment for beta‑thalassemia in some adult and pediatric patients. Beta-thalassemia is a rare, genetic blood disease, and the patients who qualify for the treatment require regular red blood cell transfusions. The one-time wholesale acquisition price for Zynteglo is $2.8 million. Bluebird also announced an outcomes-based agreement in which the company will reimburse commercial and government payers up to 80% of the total cost if a patient fails to stay transfusion-free for two years. Bluebird's stock has tumbled 25.9% so far this year, while the broader S&P 500 /zigman2/quotes/210599714/realtime SPX +2.50% is down 9.6%. fdsup://factset/Doc%20Viewer%20Single?_expand=oE8Pv7&float_window=true EST (833-888-6378) for more information, and additional details will be available at mybluebirdsupport.com in the coming days. ZYNTEGLO was reviewed under Priority Review, and the Company received a Priority Review voucher upon approval. ZYNTEGLO was previously granted Orphan Drug designation and Breakthrough Therapy designation.

/zigman2/quotes/207450173/composite
US : U.S.: Nasdaq
$ 5.99
-0.34 -5.45%
Volume: 3.55M
Oct. 3, 2022 2:08p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$488.18 million
Rev. per Employee
$53,566
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
3,675.41
+89.79 +2.50%
Volume: 2.22B
Oct. 3, 2022 2:09p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.